{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 39,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/30",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.35,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "chart",
      "text": "AVOIDING TRK INHIBITION",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "600856f8-08fa-4799-8d7e-a9decc00f0a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.15,
        "x": 0.41,
        "y": 0.22
      },
      "kind": "chart",
      "text": "BRAIN PENETRANCE",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "271d0017-956e-4ee6-b4bb-49acdf32183e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.32,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "chart",
      "text": "ACTIVITY AGAINST ALK WILD-TYPE AND MUTANTS",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1718eaa6-279f-4414-8724-b369b1ab4ae4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies. Sources: Mizuta, H. et al., WCLC 2022; Pelish, H.E. et al., AACR 2021; Data on file.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2645a316-e9a9-4e09-b032-6b138eaeba99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preclinical | NVL-655 is a Brain Penetrant, ALK-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e573b2e8-c4b7-4cdf-b3c4-339ce335773e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}